New era of biologic therapeutics in atopic dermatitis - Test2 - elhamkhani - TriplyDB

New era of biologic therapeutics in atopic dermatitis

New era of biologic therapeutics in atopic dermatitis

http://www.wikidata.org/entity/Q27001941

about

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection.Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways Osteoporosis in adult patients with atopic dermatitis: A nationwide population-based study A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.miRNAs in inflammatory skin diseases and their clinical implications.EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.New and Emerging Targeted Systemic Therapies: A New Era for Atopic Dermatitis.The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.Novel Biologicals for the Treatment of Allergic Diseases and Asthma.Chronic systemic inflammation originating from epithelial tissues.Therapeutic benefits of natural ingredients for atopic dermatitis.IL-4 driven transcription factor FoxQ1 is expressed by monocytes in atopic dermatitis and stimulates monocyte migration.The Future of Atopic Dermatitis Treatment.Ustekinumab for severe atopic dermatitis: an important negative study.Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway.

P2860

Q26799532-52B1395C-A8E3-4FE8-A130-4DCBCB1F28F7 Q27310680-9098FC06-679D-4C07-B061-584F7056A904 Q28397937-0FC7140A-8B85-44A9-B482-59E69A488E7E Q34006054-A506AC48-4FF1-49FD-AE04-327919166EA6 Q35539472-02D7D110-239B-44EE-BC85-F353945E6748 Q35803992-C8E7CF94-3D44-4FBF-998D-5D413DAD8831 Q36282512-80E891C5-0230-4EE6-ABB5-04E79696D56C Q37031192-A8B23E49-E199-4F64-B90E-F5202F80D064 Q37630234-990D07FC-BD44-4EF1-931B-4FC4CD6B24F1 Q38365504-70BEA2A7-044E-41E2-B7F2-6A95C0E06F10 Q38394577-107D38EB-3AFE-44C4-8584-D17926DBA95D Q38602326-36C825D0-8018-4F48-95E5-C4216A581AA2 Q38733182-D648095C-625D-48B1-885A-F82F04DEA3AC Q38950769-9B242146-8E93-4B3C-8C70-03EAD7D2A29D Q38960213-EDBA6829-A3F1-4AA4-8EAD-7751D3506F64 Q46710832-8CA81D0D-C473-43F1-9120-741BC547E0FD Q47116025-AA7CEF88-3270-44B4-BDF2-81A245A4F880 Q47880524-EE7C415C-3F05-4DA0-A430-D4E32D06576A Q47917146-F686EACA-603C-4DD3-ADE9-471100AE1A16 Q48205671-F800DD7F-553C-41F8-84CE-5EE8B9ACE33D

P2860

New era of biologic therapeutics in atopic dermatitis

http://www.wikidata.org/entity/Q27001941

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

New era of biologic therapeutics in atopic dermatitis

@ast

New era of biologic therapeutics in atopic dermatitis

@en

New era of biologic therapeutics in atopic dermatitis

@nl

type

label

New era of biologic therapeutics in atopic dermatitis

@ast

New era of biologic therapeutics in atopic dermatitis

@en

New era of biologic therapeutics in atopic dermatitis

@nl

prefLabel

New era of biologic therapeutics in atopic dermatitis

@ast

New era of biologic therapeutics in atopic dermatitis

@en

New era of biologic therapeutics in atopic dermatitis

@nl

P1433

Q27001941-8943C076-7921-4BDF-94FF-5FF8E8EAF7A8

P1476

Q27001941-264B6EAA-2906-4D1E-920F-D04057BE04BD

P2093

Q27001941-6DF03725-775D-497C-9A33-141C264024CC

Q27001941-C6137421-C613-4E9C-BAA6-6A4C1B520888

Q27001941-CEF33877-1177-47BD-86EE-C58104DB6164

P2860

Q27001941-00A9FC6B-DA9F-4E58-9001-EDBE8FCB695B

Q27001941-046BFFDE-4FAC-429D-8D86-A3A56F1A8049

Q27001941-0A04258E-87DB-4E3B-B8F2-D3DA961D12E0

Q27001941-10476B49-9E83-4634-B1A7-642B2678C124

Q27001941-10DA52C0-E0B5-496D-B72F-84EED8FF907C

Q27001941-11531E35-B06B-4596-B2FC-5D4A354BD16B

Q27001941-182B6EC4-F45B-4AD6-8B0D-557D484E9FB6

Q27001941-19AEE6AC-2E15-458E-A413-427C5DF16833

Q27001941-1A00FBE8-4A0D-4E4F-8437-D22427D580BE

Q27001941-1BDA468F-402C-4939-ACDB-7D7563513770

P304

Q27001941-89775937-2DC5-4AD7-9EE1-5B3F788A4241

P31

Q27001941-52911D29-2486-4733-9D1C-0366E6067BC1

P3181

Q27001941-5C022A7D-52F2-4187-8FAB-D158242D797D

P356

Q27001941-E54885A0-740C-4F32-AD1F-B9695AFBE180

P407

Q27001941-3956EFDA-8B92-4B90-BB10-1C1A7527F0AF

P433

Q27001941-52E26046-E572-4CB6-AC34-7D2BDBC858B8

P478

Q27001941-0161CB6A-D385-4C88-9FEC-76C4B5A495EB

P577

Q27001941-4D717E98-DBF3-4356-9B74-657161B293A1

P5875

Q27001941-BBCF9602-C23D-48B1-B22B-679CC750CF02

P698

Q27001941-21F3115B-624C-4691-8711-0057DEEBD495

P932

Q27001941-4248E27D-EE7D-4895-A46B-D15EF87A0D01

P3181

P356

14712598.2013.758708

P1433

Expert Opinion on Biological Therapy

P1476

New era of biologic therapeutics in atopic dermatitis

@en

P2093

Donald YM Leung

http://www.w3.org/2001/XMLSchema#string

Emma Guttman-Yassky

http://www.w3.org/2001/XMLSchema#string

Nikhil Dhingra

http://www.w3.org/2001/XMLSchema#string

P2860

IL-17 and Th17 Cells

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

Interleukin-17 and type 17 helper T cells

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

P304

549-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

567044

http://www.w3.org/2001/XMLSchema#string

P356

10.1517/14712598.2013.758708

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234156525

http://www.w3.org/2001/XMLSchema#string

P698

23323893

http://www.w3.org/2001/XMLSchema#string

P932

3819721

http://www.w3.org/2001/XMLSchema#string